SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.37+0.9%Dec 8 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (20293)6/14/2006 8:39:55 PM
From: Robohogs   of 52153
 
How about the insurers setting up special incentives (a la their diabetes programs) to get people who need to be on zocor when it goes generic.

On the switch topic, I think everyone is a bit right. I think rkrw best matches my position. There will be some switching but it will be managed with other levers - i.e., price increases for each dosage level as well as up-dosing. I would imagine something like 1/4 to 1/2 of doctors would be willing to try and move the lowest dose patients but I would imagine there would be a discussion about cost savings to the patient and agreement on the switch. Also, some patients (if and when co-pays go up) might also instigate the switch process.

Jon

PS Loving the fact that my cost of un-covered drugs is only $35 per month for Crestor (HK pricing SO much lower than US).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News